

Immuno-oncology Assay Market by Product (Consumables and Software), by Technology (Immunoassays, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Flow Cytometry), Application (Research & Development and Clinical Diagnostics), and Indication (Colorectal Cancer, Lung Cancer, Melanoma, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026

<https://marketpublishers.com/r/I6BDF55363EDEN.html>

Date: March 2020

Pages: 289

Price: US\$ 5,370.00 (Single User License)

ID: I6BDF55363EDEN

Abstracts

The global immuno-oncology assay market accounted for \$2,769.50 million in 2018, and is expected to reach \$ 6,179.20 million by 2026, growing at a CAGR of 10.6% from 2019 to 2026. Immuno-oncology assays are widely being used for the diagnosis of different types of cancer. In addition, this assay provides a gain in assay dynamic range, and is used to amplify multiple targets in a polymerase chain reaction (PCR) and collect more information from minute quantities of proteins or other analytes in lesser time. Immuno-oncology assays find its application in pathogen identification, mutation analysis, RNA detection, gene detection analysis, linkage analysis, and others.

The global immuno-oncology assay market is witnessing significant growth, owing to increase in R&D activities in pharmaceuticals for the treatment of cancer. These assays are used in clinical trials, as they decrease the cost of research & manual labor and increase the efficiency of experiments and therapies. Moreover, they allow to understand a compound's response precisely intended to mimic the tumor microenvironment. Optimized cell-based assays deliver crucial information to confirm the efficiency of a drug or a compound in simple and progressively complex co-culture

assays. In addition, they offer easier & faster analysis of cancer, and are automated as compared to conventional methods, thus fueling the market growth. However, high capital investment and dearth of skilled labors are the major factors that hinder the market growth. On the contrary, technological development of automated immuno-oncology assay is anticipated to create lucrative opportunities for market expansion in the near future.

The global immuno-oncology assay market is segmented into product, technology, indication, application, and region. On the basis of product, the market is bifurcated into consumables and software. By technology, it is classified into immunoassay, polymerase chain reaction (PCR), next-generation sequencing (NGS), flow cytometry, and others. As per indication, it is divided into colorectal cancer, lung cancer, melanoma, bladder cancer, and others. The applications covered in the study include clinical diagnostics and research. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global immune-oncology assay market along with the current trends and future estimations to elucidate the imminent investment pockets.

A comprehensive analysis of the factors that drive and restrict the market growth is provided.

A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.

An extensive analysis of the key segments of the industry helps to understand the global trends in the immune-oncology assay market.

Key players and their strategies are provided to understand the competitive outlook of the industry.

KEY MARKET SEGMENTS

By Product

Consumables

Software

By Technology

Immunoassay

PCR

NGS

Flow Cytometry

Others

By Indication

Colorectal Cancer

Lung Cancer

Melanoma

Bladder Cancer

Others

By Application

Clinical Diagnostics

Research

By Region

North America

U.S.

Canada

Mexico

Europe

UK

France

Germany

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

India

South Korea

Australia

Rest of Asia-Pacific

LAMEA

Saudi Arabia

South Africa

Brazil

Rest of LAMEA

KEY MARKET PLAYERS

Luminex Corporation

Thermo Fisher Scientific Inc.

Illumina Inc.

Bio-Rad Laboratories Inc.

QIAGEN N.V.

Becton, Dickinson and Company

Abcam PLC

Seegene Inc.

Randox Laboratories Ltd.

The other players in the value chain include (profiles not included in the report)

Merck KGaA

Agilent Technologies

Quanterix

Olink

Sysmex Corporation

Siemens Healthcare GmbH

F. Hoffmann-La Roche Ltd

Johnson & Johnson

Contents

CHAPTER 1: INTRODUCTION

- 1.1. Report description
- 1.2. Key benefits for stakeholders
- 1.3. Key market segments
- 1.4. Research methodology
 - 1.4.1. Secondary research
 - 1.4.2. Primary research
 - 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. KEY FINDINGS OF THE STUDY
- 2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

- 3.1. Market definition and scope
- 3.2. Key findings
 - 3.2.1. Top investment pockets
- 3.3. Top winning strategies
- 3.4. Porter's five forces analysis
 - 3.4.1. Moderate bargaining power of buyers
 - 3.4.2. Low bargaining power of suppliers
 - 3.4.3. Moderate threat of substitutes
 - 3.4.4. Low threat of new entrants
 - 3.4.5. Moderate competitive rivalry
- 3.5. Market share analysis, 2018
- 3.6. Market dynamics
 - 3.6.1. Drivers
 - 3.6.1.1. Increase in biotechnology R&D activities & governmental funding
 - 3.6.1.2. Surge in adoption of multiplex immuno-oncology assay to reduce operation costs
 - 3.6.1.3. Rise in adoption of personalized medicines
 - 3.6.2. Restraint
 - 3.6.2.1. Dearth of skilled labor/healthcare professionals
 - 3.6.3. Opportunity

3.6.3.1. Various growth opportunities in emerging economies

CHAPTER 4: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT

4.1. Overview

4.1.1. Market size and forecast

4.2. Consumables

4.2.1. Key market trends and opportunities

4.2.2. Market size and forecast

4.2.3. Market share analysis, by country

4.3. Software

4.3.1. Key market trends and opportunities

4.3.2. Market size and forecast

4.3.3. Market share analysis, by country

CHAPTER 5: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY

5.1. Overview

5.1.1. Market size and forecast

5.2. Immunoassays

5.2.2. Market size and forecast

5.2.3. Market share analysis, by country

5.3. Polymerase chain reaction (PCR)

5.3.1. Market size and forecast

5.3.2. Market share analysis, by country

5.4. Next-generation sequencing (NGS)

5.4.1. Market size and forecast

5.4.2. Market share analysis, by country

5.5. Flow cytometry

5.5.1. Market size and forecast

5.5.2. Market share analysis, by country

CHAPTER 6: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION

6.1. Overview

6.1.1. Market size and forecast

6.2. Colorectal cancer

6.2.1. Market size and forecast

6.2.2. Market share analysis, by country

6.3. Lung Cancer

6.3.1. Market size and forecast

6.3.2. Market share analysis, by country

6.5. Melanoma cancer

6.5.1. Market size and forecast

6.5.2. Market share analysis, by country

6.7. Bladder Cancer

6.7.1. Market size and forecast

6.7.2. Market share analysis, by country

6.9. Others

6.9.1. Market size and forecast

6.9.2. Market share analysis, by country

CHAPTER 7: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION

7.1. Overview

7.1.1. Market size and forecast

7.2. Research & development

7.2.1. Market size and forecast

7.2.2. Market share analysis, by country

7.3. Clinical diagnostics

7.3.1. Market size and forecast

7.3.2. Market share analysis, by country

CHAPTER 8: IMMUNO-ONCOLOGY ASSAY MARKET, BY REGION

8.1. Overview

8.1.1. Market size and forecast

8.2. North America

8.2.1. Key market trends and opportunities

8.2.2. Market size and forecast, by country

8.2.3. North America market size and forecast, by product

8.2.4. North America market size and forecast, by technology

8.2.5. North America market size and forecast, by indication

8.2.6. North America market size and forecast, by application

8.2.6.1. U.S. market size and forecast, by product

8.2.6.2. U.S. market size and forecast, by technology

8.2.6.3. U.S. market size and forecast, by indication

8.2.6.4. U.S. market size and forecast, by application

- 8.2.6.5. Canada market size and forecast, by product
- 8.2.6.6. Canada market size and forecast, by technology
- 8.2.6.7. Canada market size and forecast, by indication
- 8.2.6.8. Canada market size and forecast, by application
- 8.2.6.9. Mexico market size and forecast, by product
- 8.2.6.10. Mexico market size and forecast, by technology
- 8.2.6.11. Mexico market size and forecast, by indication
- 8.2.6.12. Mexico market size and forecast, by application

8.3. Europe

- 8.3.1. Key growth factors and opportunities
- 8.3.2. Market size and forecast, by country
- 8.3.3. Europe market size and forecast, by product
- 8.3.4. Europe market size and forecast, by technology
- 8.3.5. Europe market size and forecast, by indication
- 8.3.6. Europe market size and forecast, by application
 - 8.3.6.1. Germany market size and forecast, by product
 - 8.3.6.2. Germany market size and forecast, by technology
 - 8.3.6.3. Germany market size and forecast, by indication
 - 8.3.6.4. Germany market size and forecast, by application
 - 8.3.6.5. France market size and forecast, by product
 - 8.3.6.6. France market size and forecast, by technology
 - 8.3.6.7. France market size and forecast, by indication
 - 8.3.6.8. France market size and forecast, by application
 - 8.3.6.9. UK market size and forecast, by product
 - 8.3.6.10. UK market size and forecast, by technology
 - 8.3.6.11. UK market size and forecast, by indication
 - 8.3.6.12. UK market size and forecast, by application
 - 8.3.6.13. Italy market size and forecast, by product
 - 8.3.6.14. Italy market size and forecast, by technology
 - 8.3.6.15. Italy market size and forecast, by indication
 - 8.3.6.16. Italy market size and forecast, by application
 - 8.3.6.17. Rest of Europe market size and forecast, by product
 - 8.3.6.18. Rest of Europe market size and forecast, by technology
 - 8.3.6.19. Rest of Europe market size and forecast, by indication
 - 8.3.6.20. Rest of Europe market size and forecast, by application

8.4. Asia-Pacific

- 8.4.1. Key growth factors and opportunities.
- 8.4.2. Asia-Pacific market size and forecast, by country
- 8.4.3. Asia-Pacific market size and forecast, by product

8.4.4. Asia-Pacific market size and forecast, by technology

8.4.5. Asia-Pacific market size and forecast, by indication

8.4.6. Asia-Pacific market size and forecast, by application

8.4.6.1. Japan market size and forecast, by product

8.4.6.2. Japan market size and forecast, by technology

8.4.6.3. Japan Market size and forecast, by indication

8.4.6.4. Japan market size and forecast, by application

8.4.6.5. China market size and forecast, by product

8.4.6.6. China market size and forecast, by technology

8.4.6.7. China market size and forecast, by indication

8.4.6.8. China market size and forecast, by application

8.4.6.9. India market size and forecast, by product

8.4.6.10. India market size and forecast, by technology

8.4.6.11. India market size and forecast, by indication

8.4.6.12. India market size and forecast, by application

8.4.6.13. Rest of Asia-Pacific market size and forecast, by product

8.4.6.14. Rest of Asia-Pacific market size and forecast, by technology

8.4.6.15. Rest of Asia-Pacific market size and forecast, by indication

8.4.6.16. Rest of Asia-Pacific market size and forecast, by application

8.5. LAMEA

8.5.1. Key growth factors and opportunities

8.5.2. LAMEA market size and forecast, by country

8.5.3. LAMEA market size and forecast, by product

8.5.4. LAMEA market size and forecast, by technology

8.5.5. LAMEA market size and forecast, by indication

8.5.6. LAMEA market size and forecast, by application

8.5.6.1. Brazil market size and forecast, by product

8.5.6.2. Brazil market size and forecast, by technology

8.5.6.3. Market size and forecast, by indication

8.5.6.4. Brazil market size and forecast, by application

8.5.6.5. Saudi Arabia market size and forecast, by product

8.5.6.6. Saudi Arabia market size and forecast, by technology

8.5.6.7. Market size and forecast, by indication

8.5.6.8. Saudi Arabia market size and forecast, by application

8.5.6.9. South Africa market size and forecast, by product

8.5.6.10. South Africa market size and forecast, by technology

8.5.6.11. South Africa market size and forecast, by indication

8.5.6.12. South Africa market size and forecast, by application

8.5.6.13. Rest of LAMEA market size and forecast, by product

- 8.5.6.14. Rest of LAMEA market size and forecast, by technology
- 8.5.6.15. Rest of LAMEA market size and forecast, by indication
- 8.5.6.16. Rest of LAMEA market size and forecast, by application

CHAPTER 9: COMPANY PROFILES

9.1. AGILENT TECHNOLOGIES, INC.

- 9.1.1. Company overview
 - 9.1.1.1. Company snapshot
- 9.1.2. Operating business segments
- 9.1.3. Product portfolio
- 9.1.4. Business performance
- 9.1.5. Key strategic moves and developments

9.2. BIO-RAD LABORATORIES, INC.

- 9.2.1. Company overview
- 9.2.2. Company snapshot
- 9.2.3. Operating business segments
- 9.2.4. Product Portfolio
- 9.2.5. Business performance

9.3. Charles River Laboratories, Inc.

- 9.3.1. Company overview
- 9.3.2. Company snapshot
- 9.3.3. Operating business segments
- 9.3.4. Product portfolio
- 9.3.5. Business performance
- 9.3.6. Key strategic moves and developments

9.4. F. HOFFMANN-LA ROCHE LTD.

- 9.4.1. Company overview
- 9.4.2. Company snapshot
- 9.4.3. Operating business segments
- 9.4.4. Product portfolio
- 9.4.5. Business performance
- 9.4.6. Key strategic moves and developments

9.5. ILLUMINA, INC.

- 9.5.1. Company overview
- 9.5.2. Company snapshot
- 9.5.3. Operating business segments
- 9.5.4. Product portfolio
- 9.5.5. Business performance

- 9.5.6. Key strategic moves and developments
- 9.6. NanoString Technologies, Inc.
 - 9.6.1. Company overview
 - 9.6.2. Company snapshot
 - 9.6.3. Operating business segments
 - 9.6.4. Product portfolio
 - 9.6.5. Business performance
- 9.7. PERKINELMER, INC.
 - 9.7.1. Company overview
 - 9.7.2. Company snapshot
 - 9.7.3. Operating business segments
 - 9.7.4. Product portfolio
 - 9.7.5. Business performance
 - 9.7.6. Key strategic moves and developments
- 9.8. QIAGEN N.V.
 - 9.8.1. Company overview
 - 9.8.2. Company snapshot
 - 9.8.3. Operating business segments
 - 9.8.4. Product portfolio
 - 9.8.5. Business performance
 - 9.8.6. Key strategic moves and developments
- 9.9. Sartorius AG
 - 9.9.1. Company overview
 - 9.9.2. Company snapshot
 - 9.9.3. Operating business segments
 - 9.9.4. Product portfolio
 - 9.9.5. Business performance
 - 9.9.6. Key strategic moves and developments
- 9.10. THERMO FISHER SCIENTIFIC, INC.
 - 9.10.1. Company overview
 - 9.10.2. Company snapshot
 - 9.10.3. Operating business segments
 - 9.10.4. Product portfolio
 - 9.10.5. Business performance
 - 9.10.6. Key strategic moves and developments

List Of Tables

LIST OF TABLES

- TABLE 01. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION)
- TABLE 02. IMMUNO-ONCOLOGY ASSAY MARKET FOR CONSUMABLES, BY REGION, 2018–2026 (\$MILLION)
- TABLE 03. IMMUNO-ONCOLOGY ASSAY SOFTWARE MARKET, BY REGION, 2018–2026 (\$MILLION)
- TABLE 04. IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)
- TABLE 05. IMMUNO-ONCOLOGY ASSAY MARKET, FOR IMMUNOASSAY, BY REGION, 2018–2026 (\$MILLION)
- TABLE 06. IMMUNO-ONCOLOGY ASSAY MARKET FOR PCR, BY REGION, 2018–2026 (\$MILLION)
- TABLE 07. IMMUNO-ONCOLOGY ASSAY MARKET FOR NEXT GENERATION SEQUENCING (NGS), BY REGION, 2018–2026 (\$MILLION)
- TABLE 08. IMMUNO-ONCOLOGY ASSAY MARKET FOR FLOW CYTOMETRY, BY REGION, 2018–2026 (\$MILLION)
- TABLE 09. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)
- TABLE 10. IMMUNO-ONCOLOGY ASSAY MARKET FOR COLORECTAL CANCER, BY REGION, 2018–2026 (\$MILLION)
- TABLE 11. IMMUNO-ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2018–2026 (\$MILLION)
- TABLE 12. IMMUNO-ONCOLOGY MARKET FOR MELANOMA, BY REGION, 2018–2026 (\$MILLION)
- TABLE 13. IMMUNO-ONCOLOGY MARKET FOR BLADDER CANCER, BY REGION, 2018–2026 (\$MILLION)
- TABLE 14. IMMUNO-ONCOLOGY MARKET FOR OTHERS, BY REGION, 2018–2026 (\$MILLION)
- TABLE 15. IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)
- TABLE 16. IMMUNO-ONCOLOGY ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2018–2026 (\$MILLION)
- TABLE 17. IMMUNO-ONCOLOGY ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2018–2026 (\$MILLION)
- TABLE 18. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY REGION,

2018–2026 (\$MILLION)

TABLE 19. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2018–2026 (\$MILLION)

TABLE 20. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION)

TABLE 21. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 22. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 23. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 24. U.S. IMMUNO-ONCOLOGY ASSAY MARKET BY PRODUCT, 2018–2026 (\$MILLION)

TABLE 25. U.S. IMMUNO-ONCOLOGY ASSAY MARKET BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 26. US IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 27. U.S. IMMUNO-ONCOLOGY ASSAY MARKET BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 28. CANADA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION)

TABLE 29. CANADA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 30. CANADA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 31. CANADA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 32. MEXICO IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION)

TABLE 33. MEXICO IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 34. MEXICO IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 35. MEXICO IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 36. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2018–2026 (\$MILLION)

TABLE 37. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION),

TABLE 38. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 39. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 40. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 41. GERMANY IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION)

TABLE 42. GERMANY IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 43. GERMANY IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 44. GERMANY IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 45. FRANCE IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION)

TABLE 46. FRANCE IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 47. FRANCE AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 48. FRANCE IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 49. UK IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION)

TABLE 50. UK IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 51. UK IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 52. UK IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 53. ITALY IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION)

TABLE 54. ITALY IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 55. ITALY IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 56. ITALY IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 57. REST OF EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY

PRODUCT, 2018–2026 (\$MILLION)

TABLE 58. REST OF EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 59. REST OF EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 60. REST OF EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 61. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2018–2026 (\$MILLION)

TABLE 62. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION),

TABLE 63. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 64. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 65. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 66. JAPAN IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION)

TABLE 67. JAPAN IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 68. JAPAN IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 69. JAPAN IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 70. CHINA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION)

TABLE 71. CHINA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 72. CHINA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 73. CHINA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 74. INDIA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION)

TABLE 75. INDIA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 76. INDIA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 77. INDIA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 78. REST OF ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION)

TABLE 79. REST OF ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 80. REST OF ASIA PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 81. REST OF ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 82. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2018–2026 (\$MILLION)

TABLE 83. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION),

TABLE 84. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 85. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 86. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 87. BRAZIL IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION)

TABLE 88. BRAZIL IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 89. BRAZIL IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 90. BRAZIL IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 91. SAUDI ARABIA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION)

TABLE 92. SAUDI ARABIA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 93. SAUDI ARABIA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 94. SAUDI ARABIA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 95. SOUTH AFRICA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION)

TABLE 96. SOUTH AFRICA IMMUNO-ONCOLOGY ASSAY MARKET, BY

TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 97. SOUTH AFRICA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 98. SOUTH AFRICA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 99. REST OF LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 (\$MILLION)

TABLE 100. REST OF LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 (\$MILLION)

TABLE 101. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 (\$MILLION)

TABLE 102. REST OF LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 (\$MILLION)

TABLE 103. AGILENT: OPERATING SEGMENTS

TABLE 104. AGILENT: PRODUCT PORTFOLIO

TABLE 105. BIO-RAD: COMPANY SNAPSHOT

TABLE 106. BIO-RAD: OPERATING SEGMENTS

TABLE 107. BIO-RAD: PRODUCT PORTFOLIO

TABLE 108. CHARLES RIVER: COMPANY SNAPSHOT

TABLE 109. CHARLES RIVER: OPERATING SEGMENTS

TABLE 110. CHARLES RIVER: PRODUCT PORTFOLIO

TABLE 111. ROCHE: COMPANY SNAPSHOT

TABLE 112. ROCHE: OPERATING SEGMENTS

TABLE 113. ROCHE: PRODUCT PORTFOLIO

TABLE 114. ILLUMINA: COMPANY SNAPSHOT

TABLE 115. ILLUMINA: OPERATING SEGMENTS

TABLE 116. ILLUMINA: PRODUCT PORTFOLIO

TABLE 117. NANOSTRING: COMPANY SNAPSHOT

TABLE 118. NANOSTRING: PRODUCT PORTFOLIO

TABLE 119. PERKINELMER: COMPANY SNAPSHOT

TABLE 120. PERKINELMER: OPERATING SEGMENTS

TABLE 121. PERKINELMER: PRODUCT PORTFOLIO

TABLE 122. QIAGEN: COMPANY SNAPSHOT

TABLE 123. QIAGEN: OPERATING SEGMENTS

TABLE 124. QIAGEN: PRODUCT PORTFOLIO

TABLE 125. SARTORIUS: COMPANY SNAPSHOT

TABLE 126. SARTORIUS: OPERATING SEGMENTS

TABLE 127. SARTORIUS: PRODUCT PORTFOLIO

TABLE 128. THERMO FISHER: COMPANY SNAPSHOT

TABLE 129. THERMO FISHER: OPERATING SEGMENTS

TABLE 130. THERMO FISHER: PRODUCT PORTFOLIO

List Of Figures

LIST OF FIGURES

FIGURE 01. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET SEGMENTATION

FIGURE 02. TOP INVESTMENT POCKETS

FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2016–2019*

FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016–2019* (%)

FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2016–2019*

FIGURE 06. MARKET SHARE ANALYSIS, 2018

FIGURE 07. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET: DRIVERS, RESTRAINT, AND OPPORTUNITY

FIGURE 08. COMPARATIVE SHARE ANALYSIS OF IMMUNE-ONCOLOGY ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2018 & 2026 (%)

FIGURE 09. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR SOFTWARE, BY COUNTRY, 2018 & 2026 (%)

FIGURE 10. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR IMMUNOASSAY, BY COUNTRY, 2018 & 2026 (%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR PCR, BY COUNTRY, 2018 & 2026 (%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR NEXT GENERATION SEQUENCING (NGS), BY REGION, 2018–2026 (\$MILLION), BY COUNTRY, 2018 & 2026 (%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2018 & 2026 (%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2018 & 2026 (%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY MARKET FOR LUNG CANCER, BY COUNTRY, 2018 & 2026 (%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR MELANOMA, BY COUNTRY, 2018 & 2026 (%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR BLADDER CANCER, BY COUNTRY, 2018 & 2026 (%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR OTHERS , BY COUNTRY, 2018 & 2026 (%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET, FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2018 & 2026 (%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET, FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2018 & 2026 (%)

FIGURE 21. AGILENT: COMPANY SNAPSHOT

FIGURE 01. AGILENT: NET SALES, 2016–2018 (\$MILLION)

FIGURE 02. AGILENT: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 03. AGILENT: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 04. BIO-RAD: NET SALES, 2016–2018 (\$MILLION)

FIGURE 05. BIO-RAD: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 06. BIO-RAD: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 07. CHARLES RIVER: NET SALES, 2016–2018 (\$MILLION)

FIGURE 08. CHARLES RIVER: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 09. CHARLES RIVER: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 10. ROCHE: NET SALES, 2016–2018 (\$MILLION)

FIGURE 11. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 12. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 13. ILLUMINA: NET SALES, 2016–2018 (\$MILLION)

FIGURE 14. ILLUMINA: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 15. REVENUE SHARE BY REGION, 2018 (%)

FIGURE 16. NANOSTRING: NET SALES, 2016–2018 (\$MILLION)

FIGURE 17. NANOSTRING: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 18. PERKINELMER: NET SALES, 2016–2018 (\$MILLION)

FIGURE 19. PERKINELMER: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 20. PERKINELMER: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 21. QIAGEN: NET SALES, 2016–2018 (\$MILLION)

FIGURE 22. QIAGEN: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 23. QIAGEN: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 24. SARTORIUS: NET SALES, 2016–2018 (\$MILLION)

FIGURE 25. SARTORIUS: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 26. SARTORIUS: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 27. THERMA FISHER: NET SALES, 2016–2018 (\$MILLION)

FIGURE 28. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 29. THERMO FISHER: REVENUE SHARE BY REGION, 2018 (%)

I would like to order

Product name: Immuno-oncology Assay Market by Product (Consumables and Software), by Technology (Immunoassays, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Flow Cytometry), Application (Research & Development and Clinical Diagnostics), and Indication (Colorectal Cancer, Lung Cancer, Melanoma, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026

Product link: <https://marketpublishers.com/r/l6BDF55363EDEN.html>

Price: US\$ 5,370.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l6BDF55363EDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970